SAT513 Venous Thromboembolism and Thyroid Cancer. Analysis of National Inpatient Sample

Disclosure: M. Botros: None. N. Mazzaferro: None. P. Greenberg: None. D.A. Cohen: None. Introduction: Current literature describes the strong association between thrombosis risk and cancer. Multiple studies have shown a relationship between cancer and venous thromboembolism (VTE), a condition that occurs when a blood clot forms in a vein and includes deep vein thrombosis (DVT) and pulmonary embolism (PE) (1). Few European studies have shown an association between VTE and thyroid cancer (2). However, research studying the association of thyroid cancer with VTE in the United States or on a large scale is lacking. The discovery of thyroid cancer as a risk factor in the development of VTE may improve the detection of thyroid cancer and prevent future morbidity and mortality from thyroid cancer and VTE. Objectives: Using the National (Nationwide) Inpatient Sample (NIS) database, this study reports VTE incidence in various cancer types to determine if the association between VTE prevalence is higher in thyroid cancer than in other cancer types. The study also compared the coexistence of VTE and thyroid cancer in hospitalized patients to the prevalence in the general population. Methods: NIS uses ICD 9 and 10 diagnosis codes for extracting data. For this study, we obtained data for the years 2015-2017. In this analysis, we reviewed the number of patients over 18 admitted with ICD 10 codes with any of sixteen different cancer types and the diagnosis of VTE. We reviewed the literature comprehensively and selected sixteen types of cancer most commonly associated with VTE. Patients with coagulation disorders and pregnant patients with ICD-10-related codes were excluded. Other variables included smoking status, obesity, and gender. Results: Data from 3,471,240 hospitalized patients were collected. 1,662,710 (48%) were females. The cancers most commonly associated with VTE were lymphoid leukemia (22.3%), non-Hodgkin’s lymphoma (14.6 %), Hodgkin’s lymphoma (13%), pancreatic cancer (11.3%), and lung cancer (10%). The cancers with the lowest cancers VTE co-diagnosis were gall bladder (9.8%), urinary bladder (9%), stomach (9%), ovarian (8.7%), melanoma (7.7%), breast (7.2%), prostate (6.8%), uterine (6%), kidney (5.7%), colon (5.4%), and thyroid (3.3%). Conclusion: In this analysis, 3.3% of all patients with thyroid cancer carried a diagnosis of VTE. Although this suggests a relatively low risk, it is still higher than VTE incidence in the general population (0.001%) (3). The increased frequency of thyroid cancer in patients with VTE may warrant further screening for underlying thyroid cancer in patients with unprovoked PE. 1.Gervaso L, et al. Venous and Arterial Thromboembolism in Patients with Cancer. J Am Coll CardiolCardioOnc. 2021. 2.Walker AJ, et al. Incidence of venous thromboembolism in patients with cancer - A cohort study using linked United Kingdom databases. European Journal of Cancer. 3.Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med. 2001. Presentation Date: Saturday, June 17, 2023